| 颜伟健胡杨青△ 黄小红张驰徐振华李君科.促红细胞生成素对血液透析患者血浆脂联素水平及左心室肥厚的影响[J].,2011,11(12):2286-2288 |
| 促红细胞生成素对血液透析患者血浆脂联素水平及左心室肥厚的影响 |
| The Effects of Erythropoietin on Plasma Adiponectin Levels and LeftVentricular Hypertrophy in Hemodialysis Patients |
| |
| DOI： |
| 中文关键词: 脂联素 促红细胞生成素 血液透析 左心室肥厚 |
| 英文关键词: Adiponectin Erythropoietin Hemodialysis Left ventricular hypertrophy |
| 基金项目: |
|
| 摘要点击次数: 478 |
| 全文下载次数: 728 |
| 中文摘要: |
| 目的：促红细胞生成素(EPO)在维持性血液透析患者中具有保护心血管的作用，本文旨在探讨EPO 在血液透析病人中对脂
联素(ADPN)水平及左心室肥厚的影响。方法：46 名维持性血液透析患者用EPO 治疗8 周，分别在治疗前，治疗第2、4、8 周后测
定血红蛋白(Hb)，红细胞压积(Hct)，血浆白蛋白(ALB)，体重指数(BMI)，C 反应蛋白（CRP），血清铁蛋白（SF），血清铁饱和度
（TAST），ELISA 测定ADPN 水平；彩色多普勒超声测定左心室心肌重量（LVM）及计算左心室心肌重量指数（LVMI）。结果：血液
透析患者血清ADPN 水平高于正常人；用EPO 治疗2 周后即出现ADPN 水平升高，第4 周后ADPN 水平进一步升高，第8 周与
第4 周比较无明显变化；应用EPO 可降低CRP、SF 水平；ADPN 是LVMI 的重要影响因子，EPO 可改善左心室肥厚与功能。结论：
EPO 可提高血液透析患者ADPN 水平，降低CRP、SF 水平，减轻左心室肥厚。 |
| 英文摘要: |
| Objective: Erythropoietin (EPO) has protective cardiovascular effect in maintenance hemodialysis patients.This study
was designed to explore the effects of the EPO on adiponectin levels and left ventricular hypertrophy in hemodialysis patients. Methods:
46 hemodialysis patients were randomly devided into group with EPO treatment for 8 weeks, respectively, were evaluated for
hemoglobin (Hb), hematocrit (Hct), plasma albumin (ALB), weight index (BMI), C-reactive protein (CRP), serum ferritin (SF), serum
iron saturation (TAST), the plasma adiponectin was examined by ELISA before and after 2,4,8 weeks.All patients were recorded left
ventricular mass(LVM) and left ventricular mass index(LVMI) by ultrasonic cardiograph. Results: Plasma adiponectin levels were higher
in hemodialysis patients than normal; levels of adiponectin increased after EPO used 2 weeks, 4 weeks after adiponectin levels further
increased, the first 8 weeks with the first 4 weeks without significant change; The plasma CRP and SF levels were reduced after EPO
uesed.Adiponectin is an important influence factor for LVMI . EPO can improve left ventricular hypertrophy and function. Conclusion:
EPO in hemodialysis patients can increase adiponectin levels, lower CRP, SF levels of dialysis patients to reduce the risk of
cardiovascular disease, to reduce left ventricular hypertrophy. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
